Compare Smith & Nephew plc (SNN) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Thomson Reuters Corp — how do they compare? Smith & Nephew plc trades at $27.67 (market cap $11.63B), while Thomson Reuters Corp trades at $97 (market cap $42.75B). The key difference: Thomson Reuters Corp is far larger — about 3.7× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.85%). Which is the better fit depends on your goals.
| SNN | TRI | |
|---|---|---|
Market Cap | $11.63B | $42.75B |
Sector | Health | Industrials |
52-Week High | $38.53 | $173.48 |
52-Week Low | $27.80 | $76.55 |
Enterprise Value | $14.66B | $45.37B |
Dividend Yield | 2.85% | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
Thomson Reuters (TRI) trades at $98.81, down 6.5% in 24 hours, with a bearish technical signal and support near $97. The company reported Q2 2026 EPS of $0.99, beating estimates, and raised full-year revenue guidance. Revenue grew 9% organically, with strong performance in Legal, Corporates, and Tax segments. Net income margin is 21.22%, and the P/E ratio is 26.03. Recent news highlights AI expansion with the launch of the proprietary Thomson-1 LLM and a cybersecurity incident affecting its case management system.
Outlook is mixed: robust recurring revenue and AI adoption support growth, but the stock faces near-term pressure from the price drop and cybersecurity risks. Analysts maintain a buy consensus with a $113 price target, implying 14% upside. Key risks include execution on AI initiatives, competitive pressures, and potential fallout from the security breach.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
